Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RPTR-1-201 in Advanced Solid Tumors (Phase 1/2)
2025-524010-28-00Phase 2Authorised
- Sponsor
- Repertoire Immune Medicines
- Start
- Mar 2026
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 5
01
Overview
Phase 2, open-label trial of RPTR-1-201 in Nonhematologic neoplasms (2 arms), sponsored by Repertoire Immune Medicines. Primary endpoints: Phase 1: Number of participants with dose-limiting toxicities and treatment-emergent adverse events and Phase 2: Objective Response Rate (ORR) per RECIST v1.1. Planned start Mar 2026; status: authorised.
02
Drugs
RPTR-1-201
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on 2025-524010-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524010-28-00.